This difference in results may reflect a more conservative approach to using the different insulin regimens in type 2 diabetes in Sweden compared with France, as the ratio of T2D-MDI and T2D-B therapies was more equal in our study, and the hospital event rates for hypoglycaemia in the T2D-B control cohort (0.25 per 100 person-years, Table 4) were lower than those reported in the RELIEF study cohort for the 12 months prior to starting isCGM (0.73% of study population). The gene discussed is INS; the disease is type 2 diabetes mellitus.